Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases,with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. Our principal executive offices are located in Palo Alto, CA.
